Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Cancer

Pembrolizumab effective in some men with advanced prostate cancer

A study of 258 men with otherwise untreatable prostate cancer shows that the rate of disease control or response lasting six months or more was 11%, with two patients showing complete response.

Scanning electron micrograph of a prostate cancer cell

Source: Steve Gschmeissner / Science Photo Library

Study has found that immunotherapy drug pembrolizumab can benefit a subset of men with advanced, otherwise untreatable prostate cancer

Around one in ten men with advanced and otherwise untreatable prostate cancer benefit from treatment with the immunotherapy drug pembrolizumab, study results show[1].

The trial involved 258 men with prostate cancer who were no longer responding to hormonal or chemotherapy treatment. They received pembrolizumab every 3 weeks for 35 weeks or until progression or intolerable toxicity.

Across all patients, the rate of disease control or response lasting six months or more was 11%, including two patients who had a complete response. However, unlike in other tumour types treated with pembrolizumab, PD-L1 status did not predict response.

The researchers said that future studies should look at how to identify which patients will respond to pembrolizumab.

Presenting the findings at the American Society of Clinical Oncology’s annual meeting on 4 June 2018 in Chicago, Illinois, Johann de Bono from the Institute of Cancer Research, London, said: “Our study has found that immunotherapy can benefit a subset of men with advanced, otherwise untreatable prostate cancer, and these are most likely to include patients who have specific DNA repair mutations within their tumours.”

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20205250

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Scanning electron micrograph of a prostate cancer cell

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.